Terms: = Lung cancer AND SMAD3, JV15-2, 4088, ENSG00000166949, P84022, Smad3, MADH3, HsT17436, Smad 3, DKFZp686J10186, HSPC193, DKFZP586N0721, MGC60396 AND Clinical Outcome
2 results:
1. Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Cabeza Barrera J; Faus-Dáder MJ
Mutat Res Rev Mutat Res; 2019; 781():63-70. PubMed ID: 31416579
[TBL] [Abstract] [Full Text] [Related]
2. SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.
Zhang L; Li QX; Wu HL; Lu X; Yang M; Yu SY; Yuan XL
Ann Oncol; 2014 Aug; 25(8):1584-90. PubMed ID: 24928833
[TBL] [Abstract] [Full Text] [Related]
